Product Images Lenalidomide
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Lenalidomide NDC 0480-1241 by Teva Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
1 - image 1
1 - image 2
1 - image 3
1 - image 4
The text displays the results of a study that compares the effectiveness of Lenalidomide/Dex treatment to Plagebo/Dex treatment in subjects with an unspecified condition. The subjects were divided into four groups with different proportions. The results indicate that the Lenalidomide/Dex treatment had a significantly lower hazard ratio (HR) at 0.285 (95% CI between 0.210 and 0.386) and a p-value of less than 0.001, compared to Plagebo/Dex. The time to progression, measured in months, is shown on the graph.*
1 - image 5
The given text represents the results of a clinical trial study, stating the hazard ratio (HR) and confidence interval (CI) for Lenalidomide/Dex, a medication used to treat certain cancers. The Log Rank p-value is less than 0.001, indicating a statistically significant difference between the treatment group and the control group. The X-axis represents Time to Progression in months, and the Y-axis is not provided. Therefore, the graph data cannot be correctly interpreted.*
Label 2.5 mg - image 6
Each capsule contains 2.5 mg of Lenalidomide and should be stored within a temperature range of 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). It is necessary to refer to the prescribing information for dosing and administration details. The medication is dispensed with a medication guide for each patient. The warning associated with this medication is the potential for human birth defects. The serialization coding area is also provided. The manufacturer is Natco Pharma Limited in India and the medication is created for Teva Pharmaceuticals in Parsippany, NJ, with the NDC code of 0480-1241-28.*
Label 20 mg - image 7
This is a warning statement for Lenalidomide 20mg capsules with a caution for human birth defects. It is advised to store the capsules at 20°C to 25°C with a slight allowance for excursions between15°C to 30°C. The text also includes the manufacturing details of the product and advises to consult the prescribing information for proper dosing and administration. Additionally, it is recommended for a pharmacist to dispense an accompanying Medication Guide to each patient.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.